An integrated pan-cancer analysis of identifying biomarkers about the EGR family genes in human carcinomas

Hua, Youwei; Wang, Hetian; Ye, Zhiqiang; Zheng, Degao; Zhang, Xu

doi:10.1016/j.compbiomed.2022.105889

Cited by 5 publications

(3 citation statements)

References 57 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGR3 (Early Growth Response Gene 3) is an important circadian rhythm gene mainly expressed in the skin and brain, plays a crucial role in regulating sleep-wake cycles [32][33][34]. Downregulation of EGR3 has been identified as a risk factor for various types of cancer, including gastric and prostate cancers [35][36][37]. This study first found EGR3 is downregulated in melanoma, and its low expression significantly impairs survival prognosis in melanoma patients.…”

Section: Discussionmentioning

confidence: 80%

Identifying novel circadian rhythm biomarkers for diagnosis and prognosis of melanoma by an integrated bioinformatics and machine learning approach

Xu,

Zeng,

Bin

et al. 2024

Aging

View full text Add to dashboard Cite

Melanoma is a highly malignant skin tumor with poor prognosis. Circadian rhythm is closely related to melanoma pathogenesis. This study aimed to identify key circadian rhythm genes (CRGs) in melanoma and explore their potential as diagnostic and prognostic biomarkers. Microarray data of melanoma tissues and normal skins were obtained. Differentially expressed genes were identified and weighted gene co-expression network analysis (WGCNA) was performed to screen hub genes associated with melanoma. By overlapping hub genes with known CRGs, 125 melanoma-related CRGs were identified. Functional enrichment analysis revealed these CRGs were mainly involved in circadian rhythm and other cancer-related pathways. Three machine learning algorithms including LASSO regression, support vector machine-recursive feature elimination (SVM-RFE), and random forest were utilized to select key CRGs. Six CRGs (ABCC2, CA14, EGR3, FBXW7, LDHB, and PSEN2) were identified as key CRGs for melanoma diagnosis and prognosis. Diagnostic values of key CRGs were evaluated by ROC analysis in training and validation sets. Prognostic values of key CRGs were assessed by survival analysis and a multivariate Cox regression prognostic model was constructed. The prognostic model could effectively stratify melanoma patients into high- and low-risk groups with significantly different survival. A nomogram integrating clinical variables and risk score was built to predict 3-, 5- and 10-year overall survival of melanoma patients. In summary, six CRGs were identified as key genes associated with melanoma pathogenesis and may serve as promising diagnostic and prognostic biomarkers. The prognostic model and nomogram could facilitate personalized prognosis evaluation of melanoma patients.

show abstract

Section: Discussionmentioning

confidence: 80%

Identifying novel circadian rhythm biomarkers for diagnosis and prognosis of melanoma by an integrated bioinformatics and machine learning approach

Xu,

Zeng,

Bin

et al. 2024

Aging

View full text Add to dashboard Cite

show abstract

“…EGR3 has been reported to participate in various tumors and demonstrates discrepant expression trends 21 . Compared with normal cells, EGR3 expression decreases in oral squamous cell carcinoma, hepatocellular carcinoma, gastric carcinoma, etc.…”

Section: Discussionmentioning

confidence: 99%

Expression of Early Growth Response 3 in Skin Cancers

Zhou,

Deng,

Luo

et al. 2024

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

Objective: To assess the expression of early growth response 3 (EGR3) in normal skin and different types of skin tumors: cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC), melanoma (MM), and cutaneous adnexal tumors containing sebaceous carcinoma (SC), trichoepithelioma (TE) and clear cell hidradenoma (CCH). Background: EGR3, expressed in multiple organs, including skin, plays an important role in cell differentiation and tumor growth. Previous studies have shown that EGR3 suppresses tumor growth and is downregulated in various malignancies. However, its distribution in normal skin and its expression especially in skin tumors have not been studied. Materials and Methods: Samples of normal cases (n = 4), cSCC (n = 12), BCC (n = 12), MM (n = 12), SC (n = 4), TE (n = 4), and CCH (n = 4) were collected from patients treated in our department between 2018 and 2023. Immunohistochemistry was used to investigate the expression of EGR3. The results were analyzed with the description of the staining pattern and the histochemical score. Results: Immunohistochemical staining showed that EGR3 was uniquely expressed in normal skin in the granular layer and upper part of the stratum spinosum, as well as in sebaceous glands and hair follicles, but not in sweat glands. In skin cancers, BCC, SC, and TE showed positive EGR3 staining, whereas cSCC, MM, and CCH were negative. Conclusions: EGR3 has a specific expression pattern in normal skin and in skin tumors, which is important for the differential diagnosis of skin tumors, in particular for cSCC and sebaceous gland carcinoma.

show abstract

“…Genes related to cell proliferation, apoptosis, and immune activation are enumerated in the heat map (Figure 8f). Among these, Egr1, [19] a tumor suppressor gene, was significantly up-regulated in the t Bu-TPAD-BF 2 NPs + laser treatment group. Studies have shown that high expression of Id1 and Id3 in breast cancer cell lines is related to high aggressiveness and metastasis, which are major mortality factors in patients with breast cancer.…”

Section: Mechanistic Analysis Of the Synergistic Pedt And Ptt Effects...mentioning

confidence: 98%

Engineering an Organic Nanoplatform for Augmented Pyroeletroimmunotherapy

Li,

Gao,

Wang

et al. 2024

Advanced Materials

View full text Add to dashboard Cite

Photothermal immunotherapy has shown great promise in the treatment of tumor metastasis. However, the thermal resistance of tumor cells substantially compromises the treatment effect of photothermal immunotherapy. Herein, a high‐performance organic pyroelectric nanoplatform, tBu‐TPAD‐BF2 nanoparticles (NPs), was rationally engineered for the effective pyroelectroimmunotherapy of tumor metastasis. Biocompatible tBu‐TPAD‐BF2 NPs with excellent pyroelectric and photothermal conversion properties were constructed by assembling organic, low‐bandgap pyroelectric molecules with amphiphilic polymers. After internalization by tumor cells, treatment with tBu‐TPAD‐BF2 NPs caused an apparent temperature elevation upon near‐infrared (NIR) laser irradiation, inducing potent immunogenic cell death (ICD). Additionally, the temperature variations under alternating NIR laser irradiation facilitated reactive oxygen species production for pyroelectric therapy, thus promoting ICD activation and lowering thermal resistance. Importantly, in vivo assessments illustrated that tBu‐TPAD‐BF2 NPs in combination with NIR laser exposure notably inhibited primary and distant tumor proliferation and prominently retarded lung metastasis. RNA profiling revealed that treatment with tBu‐TPAD‐BF2 NPs markedly suppressed metastasis under NIR laser illumination by downregulating metastasis‐related genes and upregulating immune response‐associated pathways. Therefore, this study provides a strategy for designing high‐performance pyroelectric nanoplatforms to effectively cure tumor metastasis, thereby overcoming the inherent shortcomings of photothermal immunotherapy.This article is protected by copyright. All rights reserved

show abstract

An integrated pan-cancer analysis of identifying biomarkers about the EGR family genes in human carcinomas

Cited by 5 publications

References 57 publications

Identifying novel circadian rhythm biomarkers for diagnosis and prognosis of melanoma by an integrated bioinformatics and machine learning approach

Identifying novel circadian rhythm biomarkers for diagnosis and prognosis of melanoma by an integrated bioinformatics and machine learning approach

Expression of Early Growth Response 3 in Skin Cancers

Engineering an Organic Nanoplatform for Augmented Pyroeletroimmunotherapy

Contact Info

Product

Resources

About